New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2014
16:31 EDTDISH, LMCA, USB, XOM, BRK.B, MCO, COP, USG, WFC, BRK.A, GSK, STRZA, SU, DVA, LBTYABerkshire Hathaway gives quarterly update on stakes
NEW STAKES: Liberty Global (LBTYA). INCREASED STAKES: Wells Fargo (WFC), Exxon Mobil (XOM), Davita (DVA), USG (USG) and US Bancorp (USB). DECREASED STAKES: Suncor (SU), ConocoPhillips (COP), Liberty Media (LMCA), Starz (STRZA) and Moody's (MCO). LIQUIDATED STAKES: Dish Network (DISH) and GlaxoSmithKline (GSK).
News For B;LBTYA;WFC;XOM;DVA;USG;USB;SU;COP;LMCA;STRZA;MCO;DISH;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
March 20, 2015
07:49 EDTDISHDISH initiated with an Underperform at BMO Capital
Subscribe for More Information
07:19 EDTXOM, COPWhite House expected to unveil fracking rules today, WSJ says
Subscribe for More Information
06:37 EDTCOP, XOMOil prices fall again, Reuters reports
Subscribe for More Information
06:36 EDTDISHWeb TV companies ask internet providers for special treatment, WSJ says
Subscribe for More Information
March 19, 2015
18:14 EDTGSKGlaxoSmithKline, Theravance announce FDA panel outcome on Breo Ellipta
GlaxoSmithKline (GSK) and Theravance (THRX) announced the outcome of the joint meeting of the Pulmonary-Allergy Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee of the United States FDA regarding the supplemental New Drug Application for Breo Ellipta as a once-daily inhaled treatment for asthma in patients aged 12 years and older. The FDA Advisory Committee voted that the efficacy and safety data for FF/VI 100/25 mcg and 200/25 mcg once daily in asthma support approval in adults 18 years of age and older (16 for, 4 against). The Committee voted that the efficacy data provides substantial evidence of a clinically meaningful benefit in adults (18 for, 2 against) and that the safety in this population has been adequately demonstrated (17 for, 3 against). The Committee voted against approval for the proposed indication in 12-17 year olds (2 for, 18 against). The Committee voted that the efficacy data was not sufficient to demonstrate the benefit (4 for, 16 against) and the safety (1 for, 19 against) has not been adequately demonstrated in this sub-population. The Committee recommended that a large LABA safety trial with FF/VI should be required in adults (13 yes, 7 no) and in 12-17 year olds (17 yes, 2 no and 1 no-vote), similar to the ongoing LABA safety trials being conducted as an FDA Post-Marketing Requirement by each of the manufacturers of LABA containing asthma treatments. FDA Advisory Committees provide non-binding recommendations for consideration by the FDA. Based on these opinions and the data presented, the FDA will make its final decision on approval, which is expected on April 30.
15:12 EDTGSKFDA panel says Breo lacks efficacy data in children with asthma, Bloomberg says
Subscribe for More Information
11:53 EDTUSB, WFCU.S. banks face headwinds in unloading oil loans, WSJ says
Subscribe for More Information
08:38 EDTXOMN.J. State Assembly Judiciary Committee to hold a hearing
Subscribe for More Information
07:45 EDTCOPSenate Energy & Natural Resources Committee to hold a hearing
The Committee holds a hearing entitled, "U.S. Crude Export Policy" with Senior Vice President of IHS, Carlos Pascual and Chairman & CEO of ConocoPhillips, Ryan Lance on March 19 at 10 am. Webcast Link
07:27 EDTUSGUSG sell-off on latest lawsuit overblown, says Jefferies
Subscribe for More Information
07:26 EDTGSKFDA to hold a joint advisory committee meeting
The Pulmonary-Allergy Drugs Advisory Committee and the Drug Safety & Risk Management Advisory Committee discuss the supplemental New Drug Application (sNDA) 204275-S001, for fluticasone furoate and vilanterol dry powder for inhalation (with the brand name of BREOŽ ELLIPTAŽ), sponsored by Glaxo Group Limited (d/b/a GSK) for the once-daily treatment for asthma in patients aged 12 years and older in a meeting being held in Gaithersburg, Maryland on March 19 at 8 am. Webcast Link
07:22 EDTUSGUSG, other wallboard manufacturers named in pricing fixing suit
Subscribe for More Information
07:19 EDTXOM, COPKuwaiti minister says OPEC can't cut oil production, Bloomberg reports
Subscribe for More Information
07:10 EDTGSKTheravance announces trading in common stock halted as FDA meets on sNDA
Subscribe for More Information
07:04 EDTXOMAmerican Express confirms plans to launch Plenti loyalty program
Subscribe for More Information
March 18, 2015
10:00 EDTUSGOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:59 EDTUSGUSG downgraded to Neutral at RW Baird
Subscribe for More Information
07:30 EDTDVADeutsche Bank to hold a conference
Subscribe for More Information
06:30 EDTUSGUSG downgraded to Neutral from Outperform at RW Baird
Subscribe for More Information
06:16 EDTXOMAmerican Express to launch Plenti loyalty program this spring, WSJ reports
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use